Tzu-Fei Wang,Albert Craig Lockhart
Tzu-Fei Wang
Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to impro...
Survival of patients with squamous cell malignancies of the upper urinary tract [0.03%]
上尿路鳞状细胞癌患者的生存情况
David Berz,Tina Rizack,Sherry Weitzen et al.
David Berz et al.
Background: Carcinomas of the renal pelvis and ureter are rare diseases, accounting for only about 1% of all urogenital malignancies. Previous reports suggest that squamous cell histology is associated with inferior survi...
Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma [0.03%]
来那度胺治疗复发或难治性多发性骨髓瘤的疗效和安全性
Adrian Alegre,Isabel Vicuña,Beatriz Aguado
Adrian Alegre
Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared w...
Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors [0.03%]
伊马替尼治疗胃肠间质瘤的过去与未来
Doran Ksienski
Doran Ksienski
Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 mon...
Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib? [0.03%]
晚期肾细胞癌的药疗选择：培唑帕尼的作用是什么？
Michael R Harrison
Michael R Harrison
Over the last 6 years, the treatment of metastatic renal cell carcinoma (mRCC) has undergone dramatic changes. A better understanding of the pathogenesis and tumor biology of sporadic renal cell carcinoma has led to the approval of 6 drug r...
Paroxysmal nocturnal hemoglobinuria presenting with a left intraventricular thrombus in a patient with prior thymoma and aplastic anemia [0.03%]
原发胸腺瘤和再生障碍性贫血患者出现周期性夜间溶血性贫血并发左心室内血栓一例报告
Yazan Migdady,Adam J Olszewski
Yazan Migdady
We report the case of a 37-year old man presenting with a left ventricular cardiac thrombus in the setting of subclinical paroxysmal nocturnal hemoglobinura (PNH) developing two years after immunosuppressive therapy for thymoma-associated a...
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib [0.03%]
晚期肾细胞癌的酪氨酸激酶抑制剂治疗：帕唑帕尼为重点
Naveen S Vasudev,James M G Larkin
Naveen S Vasudev
Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the m...
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? [0.03%]
sipuleucel-t在晚期前列腺癌治疗中的作用及其管理选项
Rhonda L Bitting,Andrew J Armstrong,Daniel J George
Rhonda L Bitting
Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the Unit...
Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model [0.03%]
一种针对膀胱癌的瘤内BCG，吉西他滨，干扰素-α和白介素-2作为单药或联合疗法的抗肿瘤效果：小鼠原位膀胱癌模型研究
Zhengwen Xiao,Erich Hanel,Allan Mak et al.
Zhengwen Xiao et al.
Objective: To reduce adverse effects and improve efficacy of intravesical BCG for bladder cancer, alternative treatment options were investigated in an orthotopic rat tumor model. ...
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System [0.03%]
抑制胶质瘤生长并使肿瘤暴露于免疫系统的药物
Manuel Nieto-Sampedro,Beatriz Valle-Argos,Diego Gómez-Nicola et al.
Manuel Nieto-Sampedro et al.
Treated glioblastoma patients survive from 6 to 14 months. In the first part of this review, we describe glioma origins, cancer stem cells and the genomic alterations that generate dysregulated cell division, with enhanced proliferation and...